This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
The Zacks Analyst Blog Highlights: Moderna, Sanofi, GSK, GILD and AMGN
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Sanofi, GSK, GILD and AMGN
Roche Gets FDA Nod for Gavreto for RET Fusion-Positive NSCLC
by Zacks Equity Research
Roche's (RHHBY) lung cancer arm gets a boost with the FDA approval of Gavreto for NSCLC.
Akebia Falls as Vadadustat Fails to Meet Safety Endpoint
by Zacks Equity Research
Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shares down.
How Trading Your Own Retirement Can Fleece Your Financial Future - September 04, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Vaccine Hopes Rise Again: 4 Stocks to Watch
by Ritujay Ghosh
The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and Sanofi (SNY).
Dow Jones Tops 29,000: Will ETFs & Stocks Rally in September?
by Sanghamitra Saha
The Dow jumped above 29,000 for the first time since February on Sep 2 on low rates and vaccine hopes.
The Zacks Analyst Blog Highlights: PFE, XOM, CRM, AMGN and AAPL
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PFE, XOM, CRM, AMGN and AAPL
Stock Market News for Sep1, 2020
by Zacks Equity Research
U.S. stock markets closed mostly lower on Monday as investors booked profit after a week-long rally.
Lessons for Equity Investors From Dow Jones' Big Shake-Up
by Nilanjan Choudhury
The Dow Jones is a rare example of an index constructed on the basis of a component's share price.
Bull of the Day: Salesforce.com (CRM)
by David Borun
This brand-new Dow component continues to beat the estimates and raise guidance.
Powerful Proof Anyone Can Invest for an Early Retirement - August 31, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Bayer Submits Application for Heart Failure Drug in China
by Zacks Equity Research
Bayer (BAYRY) submits a regulatory application seeking approval for vericiguat to treat patients with symptomatic chronic heart failure in China.
Gilead's Veklury Gets FDA Nod for Expanded Use in Coronavirus
by Zacks Equity Research
Gilead's (GILD) Veklury can now be used to treat all hospitalized patients with COVID-19, in addition to severe COVID-19.
Dow Turns Green YTD in Old Format: What Will the Revamp Unfold?
by Nalak Das
The revamp is likely to make the Dow more market-friendly and reflect investors' sentiments more accurately.
More new Highs and the Best August in 36 Years
by David Borun
A change in Fed policy helps
Biotech Industry Near-Term Outlook Modest Amid Coronavirus
by Zacks Equity Research
With the coronavirus outbreak refusing to subside anytime soon, biotech companies gain focus as they race against time to evaluate every possible therapy to break the chain.
Biotech Stock Roundup: BMY to Buy Forbius, BMRN Gets CRL & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with drug approvals, and regulatory and other pipeline updates.
Why Is Amgen (AMGN) Up 0.5% Since Last Earnings Report?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Signs That Your Trading Will Ruin Your Retirement - August 27, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Dow Jones ETF in Focus on Index Shake-Up
by Sweta Killa
Given the tech sector dominance, many Wall Street analysts believe the post-reshuffle Dow Jones could struggle to catch up with the S&P 500 and the Nasdaq Composite, which have been hitting new highs.
Apple Stock Split Prompts Significant Changes in the Dow
by David Borun
The world's most widely referenced stock market index will soon swap out 10% of its holdings
AbbVie Seeks FDA Approval for Rinvoq in Ankylosing Spondylitis
by Zacks Equity Research
AbbVie (ABBV) files an application to the FDA, seeking its nod for a new indication of Rinvoq, which is active ankylosing spondylitis. The drug is already marketed to treat rheumatoid arthritis.
Stock Market News for Aug 26, 2020
by Zacks Equity Research
The S&P 500 and the Nasdaq hit an all-time high on Tuesday, while the Dow declined amid mixed economic news and decline in heavy weights like Exxon Mobil and Boeing.
Apple Stock Split Prompts Dow Reshuffle: Who's In, Who's Out?
by Tirthankar Chakraborty
Apple's stock split reduced its weight in the Dow, prompting a shake-up in the blue-chip index, with salesforce.com, Amgen and Honeywell taking Exxon, Raytheon and Pfizer's spot.
Stock Futures Mostly Higher on Trade Talks, Dow's Shake-Up in Focus
by Zacks Equity Research
This morning, Treasury Secretary Steven Mnuchin and Trade Representative Robert Lighthizer had a telephonic discussion with Chinese vice premier Liu He.